Online inquiry

IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12904MR)

This product GTTS-WQ12904MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FZD10 gene. The antibody can be applied in Synovial sarcoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_007197.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 11211
UniProt ID Q9ULW2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12904MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1392MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-981
GTTS-WQ11812MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MK-3475
GTTS-WQ10819MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M7824
GTTS-WQ10779MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA M-70
GTTS-WQ5673MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CDX-011
GTTS-WQ9601MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ8445MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HspE7
GTTS-WQ4760MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BPS-804
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW